Chancellor visits Redx labs

The Chancellor George Osborne visited Redx’s Alderley Park site in Cheshire today, meeting staff and touring the laboratories within the anti-infectives business.

He used the occasion to announce the creation of a new Catapult in Medicines Technologies. Benefitting from £5m of funding, the new Centre will also be based at Alderley Park in Cheshire.

“We very much welcome the visit of the Chancellor today”, said Redx chief executive Neil Murray. “It is always good to have the opportunity to showcase the outstanding science that our staff produce in infectious disease, cancer and immunology. The potential is clearly here to build upon the exciting progress that we have made over the last few years and we look forward to exploring how the Northern Powerhouse initiative can be harnessed to support the development of new therapies that address critical areas such as AMR and cancer.”

In terms of the news announcement, Mr Osborne told the attendant media that the best of the UK’s businesses, scientists, clinicians and engineers would work side by side in the new Catapult in Medicines Technologies. The initiative will be kick-started with £5m funding in 2015/16.

Catapult centres were launched in 2011 with the aim of bringing together businesses and researchers to help start-ups bring ideas to market that might otherwise struggle because of a lack of funding, expertise or facilities.

Mr Osborne said: “To make the most of Britain’s leading expertise in science and innovation we must back ideas at every step of the way. Today’s news and £5m investment will help put the UK in a world-leading position to support every single stage of the life sciences innovation life cycle and is exactly what is needed to develop the next generation of unbeatable British leaders in this area. I am particularly pleased to announce that Alderley Park will benefit from this investment as this is another step in putting science and innovation right at the heart of the Northern Powerhouse.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.